<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[Merz Therapeutics 보도자료 - 뉴스와이어]]></title><link>https://www.newswire.co.kr/?md=A10&amp;act=article&amp;no=45267></link><description><![CDATA[Merz Therapeutics 보도자료 - 뉴스와이어 RSS 서비스]]></description><lastBuildDate>Sat, 04 Apr 2026 04:52:22 +0900</lastBuildDate><copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright><image><url><![CDATA[https://file.newswire.co.kr/data/upfile/company_img/2024/07/12_1028147215_20240711113613_5359015674.jpg]]></url></image><language>ko-KR</language><item><title><![CDATA[Merz Therapeutics Closes $185M Asset Purchase Agreement with Acorda Therapeutics]]></title><link>https://www.newswire.co.kr/newsRead.php?no=993176</link><description><![CDATA[FRANKFURT, Germany--(Business Wire/Korea Newswire)--Merz Therapeutics announces today the successful acquisition of INBRIJA® (levodopa inhalation powder) and (F)AMPYRA® (fampridine), and related assets from Acorda Therapeutics, Inc. AMPYRA® (dalfampridine) is Food and Drug Administration (FDA) approved in the U.S. and commercialized as FAMPYRA in the European Union and other territories throughou...]]></description><image><url><![CDATA[https://file.newswire.co.kr/data/datafile2/thumb/2024/07/1028147215_20240711113545_4332252004.jpg]]></url></image><pubDate>Thu, 11 Jul 2024 11:41:38 +0900</pubDate></item><item><title><![CDATA[Merz Enters Asset Purchase Agreement With a US-Based Biotech Company]]></title><link>https://www.newswire.co.kr/newsRead.php?no=987180</link><description><![CDATA[FRANKFURT AM MAIN, Germany--(Business Wire/Korea Newswire)--Merz Therapeutics, a business of Frankfurt-based Merz Group, has entered into an Asset Purchase Agreement to acquire two commercial medicines from NASDAQ-listed Acorda Therapeutics. Closing of the transaction would significantly contribute to the accelerated growth strategy of Merz Therapeutics.  “Our specialty-neurology focused business Merz Th...]]></description><pubDate>Wed, 03 Apr 2024 15:20:00 +0900</pubDate></item><item><title><![CDATA[멀츠, 미국 기반 생명공학 회사와 자산 매입 계약 체결]]></title><link>https://www.newswire.co.kr/newsRead.php?no=987181</link><description><![CDATA[프랑크푸르트 암 마인, 독일--(Business Wire/뉴스와이어)--프랑크푸르트에 본사를 둔 멀츠 그룹(Merz Group)의 계열사인 멀츠 테라퓨틱스(Merz Therapeutics)가 나스닥 상장사 아코다 테라퓨틱스(Acorda Therapeutics)로부터 상업용 의약품 2종을 인수하는 자산 매입 계약을 체결했다. 이번 거래 체결은 메르츠 테라퓨틱스의 성장 전략 가속화에 크게 기여할 것이다.  멀츠 그룹의 COO인 요르크 베르글러(Jörg Bergler)는 “우리의 신...]]></description><pubDate>Wed, 03 Apr 2024 15:20:00 +0900</pubDate></item></channel></rss>